NeoGenomics, Inc. (NASDAQ:NEO) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET
Company Participants
Kendra Sweeney - VP of IR
Chris Smith - CEO
Jeff Sherman - CFO
Warren Stone - President of Clinical Service Division
Vishal Sikri - President of Advanced Diagnostics Division
Melody Harris - President of Enterprise Operations
Conference Call Participants
Puneet Souda - SVB Securities
David Westenberg - Piper Sandler
Dan Brennan - TD Cowen
Andrew Brackmann - William Blair
David Delahunt - Goldman Sachs
Tejas Savant - Morgan Stanley
Andrew Cooper - Raymond James
Derik De Bruin - Bank of America Merrill Lynch
Mark Massaro - BTIG
Jacob Krahenbuhl - Stephens
Operator
Welcome to the NeoGenomics First Quarter 2023 Financial Results Conference Call and Webcast. At this time all participants are in listen only mode. Please note this call is being recorded, and an audio replay will be available on the Company's website. Kendra Sweeney, Vice President of Investor Relations, you may begin your conference.
Kendra Sweeney
Thank you, Paul. Good afternoon, everyone, and welcome to the NeoGenomics first quarter financial results call. With me today to discuss the results are Chris Smith, Neo’s Chief Executive Officer and Jeff Sherman, Neo’s financial officer. Additional members of the management team are available for Q&A, including Vishal Sikri, President of Advanced Diagnostic, Warren Stone, President of Clinical Services, and Melody Harris, President of Enterprise Operations.
This call is being simultaneously webcast, we will be referring to the slide presentation that has been posted to the investors tab on our website at ir.neogenomics.com.
Starting on Slide two, during this call, we will make forward-looking statements regarding our anticipated future performance, such as our operational and financial outlooks and projections, our assumptions for that outlook, opportunities and strategies for our products and related effects on our financial and operating results.
We caution you that such statements reflect our best judgments based on factors currently known to us, and that actual events or results could differ materially, please refer to our most recent Form 10-K, 10-Q and 8-K we filed with the SEC to identify important risks and other factors that may cause our actual results to differ materially from those contained in or suggested by the forward-looking statements. The forward-looking statements made during this call speak only of the original date of the call and we undertake no obligation to update or revise any of these statements.